Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Caterpillar fungus could hold key to new osteoarthritis treatments
The caterpillar fungus Cordyceps militaris could hold the key to new treatments for osteoarthritis.

Active compound can reduce pain and halt disease progression

A fungus that infects caterpillars, Cordyceps militaris, could hold the key to new treatments for osteoarthritis, according to new research.

The study, published in the journal Scientific Reports, suggests that an active compound in the fungus, cordycepin, could reduce pain and halt disease progression.

Scientists say it works by blocking inflammation in an entirely different way to any other pain killer - by repressing a process called polyadenylation - and could be used to help patients for which other treatments have failed.

The study was led by the University of Nottingham and funded by the charity ‘Versus Arthritis’.

“We hope that cordycepin will prove to be the founder of a new class of pain killer,” explained Dr Cornelia De Moor from the University of Nottingham’s School of Pharmacy. “There is a long way to go before a cordycepin-derived medicine reaches patients, but our work is very promising, we are very excited about the prospects.”

Previous work by the University of Nottingham found that cordycepin had anti-inflammatory effects in both cartilage and bone. In this study, researchers administered the compound to rats and mice with osteoarthritis and found that it both reduced pain behaviour and structural damage.

Interestingly, researchers found that cordycepin blocked the inflammation by affecting the last stage of making a messenger RNA, Polyadenylation.

Current treatment options for osteoarthritis are limited to lifestyle changes and reducing pain with non-steroidal anti-inflammatories or opioids. But these have limited efficacy and come with unpleasant side effects.

The team hope that the results from this new research will provide a more effective treatment for osteoarthritis that is less toxic and will, therefore, have fewer side effects for patients.

Dr Stephen Simpson from Versus Arthritis said: “Although in its early stages, the study has great potential suffering pain of musculoskeletal conditions and demonstrated the high value and impact of novel discovery-led research on understanding and treating diseases.”

Image (C) Jose Ramon Pato, Coruña, España.

Become a member or log in to add this story to your CPD history

Vets launch new podcast for pet owners

News Story 1
 Two independent vets have launched a podcast to help owners strengthen their bond with pets. Dr Maggie Roberts and Dr Vanessa Howie, who have worked in both veterinary practice and major charities, are keen to use their experience to enable people to give pets a better life.

The venture, called Vets Talking Pets, provides advice and information on a range of topics, including how to select a suitable pet, where to obtain them and how to get the best out of your vet. Maggie and Vanessa will also discuss sensitive subjects, including end-of-life care, raw food diets and the cost of veterinary care.

The podcast can be found on all the usual podcast sites, including Podbean, Apple, Amazon Music and YouTube. 

Click here for more...
News Shorts
VMD issues guidance on AVM-GSL packaging

The Veterinary Medicines Directorate (VMD) has shared advice on its requirements for medicines considered AVM-GSL.

The guidance explains the information that should be on the outer package, and sets out the typical maximum pack size for an AVM-GSL product. It also describes the user-friendly language, structure and phrases required on packaging and product leaflets.

AVM-GSL products do not require discussion between the purchaser and a veterinary professional. This means that clear product information is needed to support sales choices.

The information will be useful for submitting new products to the AVM-GSL category and lowering the distribution category of products from NFA-VPS to AVM-GSL.

The VMD's guidance can be accessed here.